样式: 排序: IF: - GO 导出 标记为已读
-
PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-03-18 Prasanna Anjaneyulu Yakkala, Fatima Naaz, Syed Shafi, Ahmed Kamal
The pathways like Wingless-related integration (Wnt/β-catenin) and PI3K play an important role in colorectal cancer (CRC) development, however, their roles are distinct in the process of oncogenesi...
-
Tumor cells-derived extracellular vesicles carry circ_0064516 competitively inhibit microRNA-6805-3p and promote cervical cancer angiogenesis and tumor growth Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-03-11 Yujue Wang, Yao Xie, Xue Wang, Nian Yang, Zhao Wu, Xun Zhang
The current study tried to elucidate the regulatory role of tumor cell-derived exosomes (Exos)-circ_0064516 in angiogenesis and growth of cervical cancer.Related cirRNAs and downstream target genes...
-
The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-03-15 Oliver D Tavabie, Siamak Salehi, Varuna R Aluvihare
Morbidity and mortality from liver disease continues to rise worldwide. There are currently limited curative treatments for patients with liver failure syndromes, encompassing acute liver failure a...
-
Guillain‒barré syndrome: immunopathogenesis and therapeutic targets Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-03-12 Shan Liu, Wei Wei Zhang, Linpei Jia, Hong-Liang Zhang
Guillain‒Barré syndrome (GBS) is a group of acute immune-mediated disorders in the peripheral nervous system. Both infectious and noninfectious factors are associated with GBS, which may act as tri...
-
Combining rejuvenation interventions in rodents: a milestone in biomedical gerontology whose time has come Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-03-13 Caitlin J. Lewis, Aubrey D. de Grey
Longevity research has matured to the point where significantly postponing age-related decline in physical and mental function is now achievable in the laboratory and foreseeable in the clinic. The...
-
Considerations on the implementation of MAP4K4 inhibitors as cancer treatment Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-29 Jaime González-Montero, Mauricio Burotto
Published in Expert Opinion on Therapeutic Targets (Just accepted, 2024)
-
Targeting the hERG1 and β1 integrin complex for cancer treatment Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-19 Annarosa Arcangeli, Jessica Iorio, Claudia Duranti
Despite great advances, novel therapeutic targets and strategies are still needed, in particular for some carcinomas in the metastatic stage (breast cancer, colorectal cancer, pancreatic ductal ade...
-
TGF-β as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-19 Nikolaos G. Frangogiannis
Myocardial fibrosis accompanies most cardiac conditions and can be reparative or maladaptive. Transforming Growth Factor (TGF)-β is a potent fibrogenic mediator, involved in repair, remodeling, and...
-
The potential for OGG1 inhibition to be a therapeutic strategy for pulmonary diseases Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-12 Lang Pan, Istvan Boldogh
Pulmonary diseases impose a daunting burden on healthcare systems and societies. Current treatment approaches primarily address symptoms, underscoring the urgency for the development of innovative ...
-
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-12 Ilan Bruchim, Ilaria Capasso, Ariel Polonsky, Shilhav Meisel, Vanda Salutari, Haim Werner, Domenica Lorusso, Giovanni Scambia, Francesco Fanfani
Endometrial cancer (EC) is the only gynecologic malignancy showing increasing trends in incidence and mortality. While standard treatment has been effective primarily for early-stage EC, precision ...
-
Kv1.3 in the spotlight for treating immune diseases Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-07 María Navarro-Pérez, Jesusa Capera, Anna Benavente-Garcia, Silvia Cassinelli, Magalí Colomer-Molera, Antonio Felipe
Kv1.3 is the main voltage-gated potassium channel of leukocytes from both the innate and adaptive immune systems. Channel function is required for common processes such as Ca2+ signaling but also f...
-
Role of the P2Y12 receptor on thrombus formation and evolution in therapeutic strategies Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-02-06 Mattia Galli, Dominick J. Angiolillo
Published in Expert Opinion on Therapeutic Targets (Vol. 28, No. 1-2, 2024)
-
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-01-26 Alessandra Merlini, Martina Rabino, Silvia Brusco, Valeria Pavese, Debora Masci, Dario Sangiolo, Paolo Bironzo, Giorgio Vittorio Scagliotti, Silvia Novello, Lorenzo D’Ambrosio
Soft tissue sarcomas are a group of rare, mesenchymal tumors characterized by dismal prognosis in advanced/metastatic stages. Knowledge of their molecular determinants is still rather limited. Howe...
-
Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-01-23 Lin Chen, Tian Fan, Miao Wang, Chun-Yu Zhu, Wang-You Feng, Yu Li, Hong Yang
Ovarian cancer (OC) is the most lethal gynecological tumor, but it currently lacks effective therapeutic targets. CD147, which is overexpressed in OC, plays a crucial role in promoting malignant pr...
-
Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel disease Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-01-23 Christoph Garbers, Juliane Lokau
Inflammatory bowel disease (IBD) is an umbrella term that includes different chronic inflammatory diseases of the gastrointestinal tract, most commonly Crohn’s disease and ulcerative colitis. IBD a...
-
Mitochondrial permeability transition pore: a snapshot of a therapeutic target Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2024-01-19 Mario Zoratti, Lucia Biasutto, Sofia Parrasia, Ildikó Szabo
Published in Expert Opinion on Therapeutic Targets (Vol. 28, No. 1-2, 2024)
-
Advances in targeting the extracellular matrix for glaucoma therapy: current updates Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Renu Agarwal, Igor Iezhitsa
Elevated intraocular pressure (IOP) is a well-recognized risk factor for development of primary open angle glaucoma (POAG), a leading cause of irreversible blindness. Ocular hypertension is associa...
-
miR-26a-5p restoration via EZH2 silencing blocks the IL-6/STAT3 axis to repress the growth of prostate cancer Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Wenqiang Zhang, Qiwei Nie, Xuling Zhang, Long Huang, Guofu Pang, Jing Chu, Xiaoxu Yuan
Interleukin-6 (IL-6) is involved in the activation of several oncogenic pathways in prostate cancer. However, its upstream trans-signaling pathway remains largely unknown. This work proposes a mech...
-
Targeting GABA receptors with chalcone derivative compounds, what is the evidence? Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Feba Benny, Sunil Kumar, Aiswarya Binu, Della Grace Thomas Parambi, Tariq G. Alsahli, Abdullah G. Al-Sehemi, Namitha Chandran, Deepthi S. Manisha, Sarath Sreekumar, Akanksha Bhatt, Krishnadas Madhu, Bijo Mathew
In medicinal chemistry, privileged structures have been frequently exploited as a successful template for drug discovery. Common simple scaffolds like chalcone are present in a wide range of natura...
-
Novel signatures of prostate cancer progression and therapeutic resistance Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Jason Wang, Reuben Ben-David, Reza Mehrazin, Wei Yang, Ashutosh K. Tewari, Natasha Kyprianou
The extensive heterogeneity of prostate cancer (PCa) and multilayered complexity of progression to castration-resistant prostate cancer (CRPC) have contributed to the challenges of accurately monit...
-
XBP1 as a novel molecular target to attenuate drug resistance in hepatocellular carcinoma Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Zahra Hendi, Pedram Asadi Sarabi, David Hay, Massoud Vosough
Despite improvements in clinical management of hepatocellular carcinoma (HCC), prognosis remains poor with a 5-year survival rate less than 40%. Drug resistance in HCC makes it challenging to treat...
-
Unraveling therapeutic targets in acute myeloid leukemia through multiplexed genome editing CRISPR screening Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Zhen Tian, Stacia Octaviani, Jian Huang
Published in Expert Opinion on Therapeutic Targets (Vol. 27, No. 12, 2023)
-
How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy? Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Paolo Baldo, Valli De Re, Mattia Garutti
Mapping of the human genome, together with the broad understanding of new biomolecular pathways involved in cancer development, represents a huge dividing line for advances in cancer treatment. Thi...
-
Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Masoud Sotoudeh, Vahid Mansouri, Ramin Shakeri, Bahareh Sharififard, Nasim Sajadi, Vahid Haghpanah, Mahmood Naderi
Despite the promise of immunotherapy for gastric adenocarcinoma, resistance is common, necessitating the validation of new targets. Based on our previous bioinformatics analysis, the MUC3A antigen ...
-
Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Cristi L. Galindo, Saifur Khan, Xiangyu Zhang, Yu-Sheng Yeh, Ziyang Liu, Babak Razani
Lipid-laden foam cells within atherosclerotic plaques are key players in all phases of lesion development including its progression, necrotic core formation, fibrous cap thinning, and eventually pl...
-
Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Jessica D. Johnson, Salvador Alejo, Sridharan Jayamohan, Gangadhara R. Sareddy
Lysine-specific histone demethylase 1A (KDM1A/LSD1) has emerged as an important therapeutic target in various cancer types. LSD1 regulates a wide range of biological processes that influence cancer...
-
Navigating the landscape of psoriasis therapy: novel targeted pathways and emerging trends Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-30 Srinath Innani, Yashika Tomar, Vikas Rana, Gautam Singhvi
Psoriasis is a chronic, inflammatory, non-communicable skin disorder that affects a patient’s social and emotional well-being. It is characterized by hyperproliferation of keratinocytes, irregular ...
-
Powering down the mitochondrial LonP1 protease: a novel strategy for anticancer therapeutics Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-29 Rahul Shetty, Roberto Noland, Ghata Nandi, Carolyn K. Suzuki
Mitochondrial LonP1 is an ATP-powered protease that also functions as an ATP-dependent chaperone. LonP1 plays a pivotal role in regulating mitochondrial proteostasis, metabolism and cell stress res...
-
Interleukin-18 in cancer immunology and immunotherapy Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Assunta Cirella, Irene Olivera, Carlos Luri-Rey, Elixabet Bolaños, Pedro Berraondo, Ignacio Melero
Interleukin-18 (IL-18) is a myeloid leukocyte inflammatory mediator whose main known function is to elicit IFNγ secretion from T and NK cells.This function offers potential in cancer immunotherapy ...
-
Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Laura D. Carreira, Rita I. Oliveira, Vânia M. Moreira, Jorge A. R. Salvador
Ubiquitin-specific protease 7 (USP7) also known as herpesvirus-associated ubiquitin-specific protease (HAUSP) is a well-characterized cysteine protease that belongs to the largest subfamily of deub...
-
Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Julian S. Rechberger, Samantha M. Bouchal, Erica A. Power, Leo F. Nonnenbroich, Cody L. Nesvick, David J. Daniels
H3 K27-altered diffuse midline glioma (DMG) is the most common malignant brainstem tumor in the pediatric population. Despite enormous preclinical and clinical efforts, the prognosis remains dismal...
-
CDK6: an attractive therapeutic target for T-ALL/LBL Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Wei Li, Jamie Katy Hu, Miaofen G Hu
Human T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/LBL) is a type of cancer that originates from the bone marrow and spreads quickly to other organs. Long-term survival ...
-
Targeting cyclin-dependent kinases in rheumatoid arthritis and psoriasis – a review of current evidence Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Marzena Staniszewska, Kajetan Kiełbowski, Klaudia Rusińska, Estera Bakinowska, Ewa Gromowska, Andrzej Pawlik
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with synovial proliferation and bone erosion, which leads to the structural and functional impairment of the joints. Immune ce...
-
Interleukin-1 family cytokines in liver cell death: a new therapeutic target for liver diseases Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Wanvisa Udomsinprasert
Liver cell death represents a basic biological process regulating the progression of liver diseases via distinct mechanisms. Accumulating evidence has uncovered participation of interleukin (IL)-1 ...
-
Vitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Jingqi Liu, Yang Song, Ye Wang, Huashan Hong
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, but underlying mechanisms are not fully understood. In recent years, a growing body of evidenc...
-
The anti-inflammatory and vasoprotective properties of mPGES-1 inhibition offer promising therapeutic potential Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Julia Steinmetz-Späh, Per-Johan Jakobsson
Prostaglandin E2 (PGE2) is produced by cyclooxygenases (COX-1/2) and the microsomal prostaglandin E synthase 1 (mPGES-1). PGE2 is pro-inflammatory in diseases such as rheumatoid arthritis, cardiova...
-
Calcium channelopathies in neurodegenerative disorder: an untold story of RyR and SERCA Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Maanvi Dhureja, Richmond Arthur, Divya Soni, Shubham Upadhayay, Pooja Temgire, Puneet Kumar
Recent neuroscience breakthroughs have shed light on the sophisticated relationship between calcium channelopathies and movement disorders, exposing a previously undiscovered tale focusing on the R...
-
Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 Jean-Baptiste Assié, Didier Jean
Pleural mesothelioma is a rare and aggressive cancer originating in the pleura, with a devastating prognosis and limited treatment options. There have been significant advancements in the managemen...
-
Feasibility and considerations of epsin2 as a candidate target for multiple system atrophy treatment Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-07 An Cheng, Bo Cai, Kohji Fukunaga, Takuya Sasaki, Aparna Lakkaraju
Published in Expert Opinion on Therapeutic Targets (Vol. 27, No. 11, 2023)
-
Leveraging AI to identify dual-purpose aging and disease targets Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-12-01 Geoffrey Ho Duen Leung, Chun Wai Wong, Frank W. Pun, Alex Aliper, Feng Ren, Alex Zhavoronkov
Published in Expert Opinion on Therapeutic Targets (Ahead of Print, 2023)
-
An overview of novel antimicrobial carbonic anhydrase inhibitors Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Claudiu T Supuran
Four different genetic families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) are present in bacteria, α-, β-, γ- and ι-CAs. They play relevant functions related to CO2, HCO3−/H+ ions homeostas...
-
Efflux systems as a target for anti-biofilm nanoparticles: perspectives on emerging applications Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Robert Musiol
Understanding the role of efflux pumps in biofilm resistance provides valuable insights for developing effective therapeutic strategies. Drugs designed for targeting efflux pumps in drug design hol...
-
Mitochondria makeover: unlocking the path to healthy Longevity Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Andrés Caicedo, Keshav K. Singh
Published in Expert Opinion on Therapeutic Targets (Just accepted, 2023)
-
OXPHOS-targeting drugs in oncology: new perspectives Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Balaraman Kalyanaraman, Gang Cheng, Micael Hardy, Ming You
Drugs targeting mitochondria are emerging as promising antitumor therapeutics in preclinical models. However, a few of these drugs have shown clinical toxicity. Developing mitochondria-targeted mod...
-
Advances in cerebellar disorders: pre-clinical models, therapeutic targets, and challenges Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Mario Manto, Jan Cendelin, Michael Strupp, Hiroshi Mitoma
Cerebellar ataxias (CAs) represent neurological disorders with multiple etiologies and a high phenotypic variability. Despite progress in the understanding of pathogenesis, few therapies are availa...
-
Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Subarno Paul, Subhajit Chatterjee, Saptarshi Sinha, Somya Ranjan Dash, Rajalaxmi Pradhan, Biswajit Das, Kunal Goutam, Chanakya Nath Kundu
Sensitization of mismatch repair (MMR)-deficient colorectal cancer (CRC) cells by 5-Fluorouracil (5-FU) is well-documented. But not much is known about the treatment of MMR-proficient CRC cancer st...
-
A1BG-AS1 promotes the biological functions of osteosarcoma cells via regulating the microRNA-148a-3p/USP22 axis and stabilizing the expression of SIRT1 through deubiquitinase function Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Xiuxin Han, Mengfan Yin, Chen Gong, Chao Zhang, Genbao Zhu, Mengxue Hu, Kemeng Tan, La Jiang, Guowen Wang, Lili Li
The study aims to explore the role of A1BG antisense RNA 1 (A1BG-AS1), microRNA (miR)-148a-3p and ubiquitin-specific protease 22 (USP22) on osteosarcoma (OS) cell growth.A1BG-AS1, miR-148a-3p, USP2...
-
Curing age-related disease, transforming global medicine Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Michael Fossel
Published in Expert Opinion on Therapeutic Targets (Ahead of Print, 2023)
-
Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Mariana Laureano de Souza, Thibault Joseph William Jacques Dit Lapierre, gabriel Vitor de Lima Marques, Witor Ribeiro Ferraz, André Berndt Penteado, Gustavo Henrique Goulart Trossini, Silvane Maria Fonseca Murta, renata Barbosa de Oliveira, celso de Oliveira Rezende Jr, Rafaela Salgado Ferreira
Chagas disease (CD) imposes social and economic burdens, yet the available treatments have limited efficacy in the disease’s chronic phase and cause serious adverse effects. To address this challen...
-
Regulatory mechanism underlying liver X receptor effects on the tumor microenvironment, inflammation and tumorigenesis Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Heng Zhang, Jing Wang, Jiang Sun, Qiang Wang, Lanfang Guo, Xiaoli Ju
Liver X receptors (LXRs) have emerged as novel targets for tumor treatment. LXRs within the tumor microenvironment show the capacity to impact tumorigenesis and tumor development by regulating the ...
-
Understanding the role of galectins toward influenza A virus infection Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-30 Zih-Syuan Yang, Chih-Yen Lin, Muhammad Bilal Khan, Ming-Cheng Hsu, Wanchai Assavalapsakul, Arunee Thitithanyanont, Sheng-Fan Wang
Influenza A virus (IAV) is highly contagious and causes respiratory diseases in birds, mammals, and humans. Some strains of IAV, whether from human or avian sources, have developed resistance to ex...
-
Can we suppress chronic systemic inflammation and postpone age-related diseases by targeting the IgG glycome? Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-28 GordAn Lauc
Glycans attached to immunoglobulin G are an important regulator of chronic systemic inflammation, one of the key drivers of aging. As people age, glycans that suppress inflammation are being replac...
-
Exosomes as a drug delivery tool for cancer therapy: a new era for existing drugs and oncolytic viruses Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-10-13 Yoshihiko Kakiuchi, Shinji Kuroda, Nobuhiko Kanaya, Shunsuke Kagawa, Hiroshi Tazawa, Toshiyoshi Fujiwara
Exosomes are cell-derived nanovesicles involved in cell-to-cell communications. These nanovesicles are generally considered to contain important carriers of information such as DNA and RNA, and sho...
-
The neuroinflammatory astrocytic P2X7 receptor: Alzheimer’s disease, ischemic brain injury, and epileptic state Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-15 Young Ha Ahn, Yong Tang, Peter Illes
Astrocytes have previously been considered as cells supporting neuronal functions, but they are now recognized as active players in maintaining central nervous system (CNS) homeostasis. Astrocytes ...
-
Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-15 Basharat Ahmad Bhat, Ifra Saifi, Nizar A. Khamjan, Syed Suhail Hamdani, Abdullah Algaissi, Safeena Rashid, Mohammed M. Alshehri, Showkat Ahmad Ganie, Mohtashim Lohani, Siddig Ibrahim Abdelwahab, Sajad Ahmad Dar
Despite cancer treatment strides, mortality due to ovarian cancer remains high globally. While immunotherapy has proven effective in treating cancers with low cure rates, it has limitations. Growin...
-
Galectin-3: therapeutic targeting in liver disease Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-15 Alison C. Mackinnon, Dimitar Tonev, Brian Jacoby, Massimo Pinzani, Robert J. Slack
The rising incidence of liver diseases is a worldwide healthcare concern. However, the therapeutic options to manage chronic inflammation and fibrosis, the processes at the basis of morbidity and m...
-
Fatty acid-mediated signaling as a target for developing type 1 diabetes therapies Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-14 Ivo Díaz Ludovico, Soumyadeep Sarkar, Emily Elliott, Suvi M. Virtanen, Iris Erlund, Sasanka Ramanadham, Raghavendra G. Mirmira, Thomas O. Metz, Ernesto S. Nakayasu
Type 1 diabetes (T1D) is an autoimmune disease in which pro-inflammatory and cytotoxic signaling drive the death of the insulin-producing β cells. This complex signaling is regulated in part by fat...
-
Habenular molecular targets for depression, impulsivity, and addiction Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-14 Snigdha Srivastava, Benjamin R Arenkiel, Ramiro Salas
Published in Expert Opinion on Therapeutic Targets (Vol. 27, No. 9, 2023)
-
The role of ubiquitination in microbial infection induced endothelial dysfunction: potential therapeutic targets for sepsis Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-14 Junshuai Wang, Yang He, Daixing Zhou
The ubiquitin system is an evolutionarily conserved and universal means of protein modification that regulates many essential cellular processes. Endothelial dysfunction plays a critical role in th...
-
Tolperisone induces UPR-mediated tumor inhibition and synergizes with proteasome inhibitor and immunotherapy by targeting LSD1 Expert Opin. Ther. Targets (IF 5.8) Pub Date : 2023-09-13 Wei Jiang, Zhiwei Yang, Pu Chen, Man Zhao, Yubo Wang, Jingyuan Wang, Xinru Li, Meichen Wang, Peng Hou
Drug repurposing is an attractive strategy for extending the arsenal of oncology therapies. Tolperisone is an old centrally acting muscle relaxant used for treatment of chronic pain conditions. In ...